🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. ATRN-119

    Aprea Therapeutics

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  2. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  3. AUTO3

    Autolus GmbH

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 mab terminated

    1 trial

  4. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  5. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  6. AV-101

    Vistagen Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  7. AVTX-801

    Ultragenyx UK Limited

    SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

    phase 2 small molecule active

    1 trial

  8. AZD0901, Rilvegostomig, DS-8201a

    AstraZeneca AB

    Locally Advanced Resectable Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. AZD3632, AZD3632

    AstraZeneca AB

    Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

    phase 2 small molecule active

    1 trial

  10. AZD4360

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. AZD5363

    Cardiff Oncology

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial

  12. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  13. Abatacept

    Ultragenyx UK Limited

    Takayasu's Arteritis

    phase 2 small molecule completed

    1 trial

  14. Abatacept

    Ultragenyx UK Limited

    Wegener's Granulomatosis

    phase 2 small molecule completed

    1 trial

  15. Abemaciclib

    KAZIA THERAPEUTICS LTD

    CDK Gene Mutation

    phase 2 small molecule active

    1 trial

  16. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN, VALPROIC ACID, SIMVASTATIN, CAPECITABINE, VALPROIC ACID, GEMCITABINE

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  17. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  18. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  20. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  21. Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial

  22. Aceneuramic Acid Extended-Release

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 2 small molecule terminated

    1 trial

  23. Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, Tora-Dol 30 mg/ml soluzione iniettabile

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 2 small molecule active

    1 trial

  24. Active Comparator CT1812

    COGNITION THERAPEUTICS INC

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources